These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11261337)

  • 21. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia.
    Stellbrink C; Auricchio A; Diem B; Breithardt OA; Kloss M; Schöndube FA; Klein H; Messmer BJ; Hanrath P
    Am J Cardiol; 1999 Mar; 83(5B):143D-150D. PubMed ID: 10089857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators.
    Tandri H; Griffith LS; Tang T; Nasir K; Zardkoohi O; Reddy CV; Capps M; Calkins H; Donahue JK
    Heart Rhythm; 2006 Jul; 3(7):762-8. PubMed ID: 16818202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure.
    Böcker D; Bänsch D; Heinecke A; Weber M; Brunn J; Hammel D; Borggrefe M; Breithardt G; Block M
    Circulation; 1998 Oct; 98(16):1636-43. PubMed ID: 9778329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining electrical therapies for advanced heart failure: the Milan experience with biventricular pacing-defibrillation backup combination for primary prevention of sudden cardiac death.
    Pappone C; Vicedomini G; Augello G; Mazzone P; Nardi S; Rosanio S
    Am J Cardiol; 2003 May; 91(9A):74F-80F. PubMed ID: 12729853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.
    Salerno-Uriarte JA; De Ferrari GM; Klersy C; Pedretti RF; Tritto M; Sallusti L; Libero L; Pettinati G; Molon G; Curnis A; Occhetta E; Morandi F; Ferrero P; Accardi F;
    J Am Coll Cardiol; 2007 Nov; 50(19):1896-904. PubMed ID: 17980258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
    Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
    Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
    J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of Patients with Advanced Heart Failure Who Receive Device-Based Therapy for Primary Prevention of Sudden Cardiac Death: Insights from the Israeli ICD Registry.
    Suleiman M; Goldenberg I; Samniah N; Rosso R; Marai I; Pekar A; Khalameizer V; Militianu A; Glikson M
    Pacing Clin Electrophysiol; 2015 Jun; 38(6):738-45. PubMed ID: 25754272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of mortality in patients undergoing cardiac resynchronization therapy: baseline clinical, echocardiographic, and angioscintigraphic evaluation prior to resynchronization.
    de Sisti A; Toussaint JF; Lavergne T; Ollitrault J; Abergel E; Paziaud O; Ait Said M; Sader R; LE Heuzey JY; Guize L
    Pacing Clin Electrophysiol; 2005 Dec; 28(12):1260-70. PubMed ID: 16403157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility for biventricular pacing in patients with an implantable cardioverter defibrillator.
    Molhoek SG; Bax JJ; van Erven L; Steendijk P; van der Wall EE; Schalij MJ
    Eur J Heart Fail; 2003 Jun; 5(3):315-7. PubMed ID: 12798829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.